Caredx (CDNA) Stock News
$CDNA · NASDAQ · 5 stories in 30 daysBORSA has published 5 stories on Caredx (CDNA) in the past 30 days, 1 of them high impact. BORSA’s news read on CDNA is bullish at 64/100, unchanged over 24 hours, based on 4 company events over the past 7 days. CDNA last closed at $71.52 on Oct 29, up 3.41% over five sessions and up 10.03% over the past month.
The wire on $CDNA
newest first · updated · direct subject stories onlyCareDx (CDNA) reported Q3 2026 revenue of $139M, up 39% YoY, with Testing Services revenue of $119M (+65% YoY) and volume of ~75,900 tests (+51% YoY). GAAP net income was $19M vs $2M a year ago. Adjusted EBITDA rose to $30M from $15M. The company raised full-year 2026 revenue guidance to $520-530M (from $490-500M) and Adjusted EBITDA guidance to $90-100M (from $66-78M). CareDx closed the acquisition of Naveris for $160M cash plus up to $100M contingent consideration. Pipeline advances include AlloHeme and HistoMap Kidney targeting 2027 launches.
bullish 85 · impact 80CareDx reported third-quarter adjusted earnings per share of 70 cents.